Respiratory syncytial virus inhibitor AZ-27 differentially inhibits different polymerase activities at the promoter

Journal of Virology

Volumn 89, Issue 15, 2015, Pages 7786-7798

  Noton, Sarah L ^a   Nagendra, Kartikeya ^a   Dunn, Ewan F ^b   Mawhorter, Michael E ^a   Yu, Qin ^b   Fearns, Rachel ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZ 27; CHLORAMPHENICOL ACETYLTRANSFERASE; GLYCOPROTEIN L; NONSTRUCTURAL PROTEIN 1; PLACEBO; POL PROTEIN; PROTEIN M2; RNA DIRECTED RNA POLYMERASE; RNA DIRECTED RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; AZ-27 COMPOUND; BENZAZEPINE DERIVATIVE; ENZYME INHIBITOR; NICOTINAMIDE; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBUNIT; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RNA SYNTHESIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRUS GENOME; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; VIROLOGY;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ANTIVIRAL AGENTS; BENZAZEPINES; ENZYME INHIBITORS; HUMANS; NIACINAMIDE; PROMOTER REGIONS, GENETIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RNA REPLICASE; TRANSCRIPTION, GENETIC; VIRAL PROTEINS;

EID: 84937694587     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00530-15     Document Type: Article

References (54)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
2. Robinson RF. 2008. Impact of respiratory syncytial virus in the United States. Am J Health Syst Pharm 65:S3-S6. http://dx.doi.org/10.2146/ajhp080438.
3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. NEngl J Med 352:1749-1759. http://dx.doi.org/10.1056/NEJMoa043951.
4. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162: 80-99. http://dx.doi.org/10.1016/j.virusres.2011.09.020.
5. Krilov LR. 2011. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti Infect Ther 9:27-32. http://dx.doi.org/10.1586/eri.10.140.
6. Chu HY, Englund JA. 2013. Respiratory syncytial virus disease: prevention and treatment. Curr Top Microbiol Immunol 372:235-258.
7. DeVincenzo JP, El Saleeby CM, Bush AJ. 2005. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 191:1861-1868. http://dx.doi.org/10.1086/430008.
8. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E, Oxford J, Pareek R, Moore R, Walsh E, Studholme R, Dorsett P, Alvarez R, Lambkin-Williams R. 2010. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 182: 1305-1314. http://dx.doi.org/10.1164/rccm.201002-0221OC.
9. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP. 2011. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 204:996-1002. http://dx.doi.org/10.1093/infdis/jir494.
10. DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, McBride S, Lambkin-Williams R, Jordan R, Xin Y, Ramanathan S, O'Riordan T, Lewis SA, Li X, Toback SL, Lin SL, Chien JW. 2014. Oral GS-5806 activity in a respiratory syncytial virus challenge study. NEngl J Med 371:711-722. http://dx.doi.org/10.1056/NEJMoa1401184.
11. Collins PL, Fearns R, Graham BS. 2013. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol 372:3-38. http://dx.doi.org/10.1007/978-3-642-38919-1_1.
12. Morin B, Kranzusch PJ, Rahmeh AA, Whelan SP. 2013. The polymerase of negative-stranded RNA viruses. Curr Opin Virol 3:103-110. http://dx.doi.org/10.1016/j.coviro.2013.03.008.
13. Bujnicki JM, Rychlewski L. 2002. In silico identification, structure prediction and phylogenetic analysis of the 2'-O-ribose (cap 1) methyltransferase domain in the large structural protein of ssRNA negative-strand viruses. Protein Eng 15:101-108. http://dx.doi.org/10.1093/protein/15.2.101.
14. Fix J, Galloux M, Blondot ML, Eleouet JF. 2011. The insertion of fluorescent proteins in a variable region of respiratory syncytial virus L polymerase results in fluorescent and functional enzymes but with reduced activities. Open Virol J 5:103-108. http://dx.doi.org/10.2174/1874357901105010103.
15. Liuzzi M, Mason SW, Cartier M, Lawetz C, McCollum RS, Dansereau N, Bolger G, Lapeyre N, Gaudette Y, Lagace L, Massariol MJ, Do F, Whitehead P, Lamarre L, Scouten E, Bordeleau J, Landry S, Rancourt J, Fazal G, Simoneau B. 2005. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNAdependent RNA polymerase. J Virol 79:13105-13115. http://dx.doi.org/10.1128/JVI.79.20.13105-13115.2005.
16. Noton SL, Deflube LR, Tremaglio CZ, Fearns R. 2012. The respiratory syncytial virus polymerase has multiple RNA synthesis activities at the promoter. PLoS Pathog 8:e1002980. http://dx.doi.org/10.1371/journal.ppat.1002980.
17. Poch O, Blumberg BM, Bougueleret L, Tordo N. 1990. Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains. J Gen Virol 71(Part 5):1153-1162. http://dx.doi.org/10.1099/0022-1317-71-5-1153.
18. Poch O, Sauvaget I, Delarue M, Tordo N. 1989. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 8:3867-3874.
19. Li J, Rahmeh A, Morelli M, Whelan SP. 2008. A conserved motif in regionVof the large polymerase proteins of nonsegmented negative-sense RNA viruses that is essential for mRNA capping. J Virol 82:775-784. http://dx.doi.org/10.1128/JVI.02107-07.
20. Ogino T, Banerjee AK. 2007. Unconventional mechanism of mRNA capping by the RNA-dependent RNA polymerase of vesicular stomatitis virus. Mol Cell 25:85-97. http://dx.doi.org/10.1016/j.molcel.2006.11.013.
21. Barr JN, Wertz GW. 2001. Polymerase slippage at vesicular stomatitis virus gene junctions to generate poly(A) is regulated by the upstream 3'-AUAC-5' tetranucleotide: implications for the mechanism of transcription termination. J Virol 75:6901-6913. http://dx.doi.org/10.1128/JVI.75.15.6901-6913.2001.
22. Barr JN, Whelan SP, Wertz GW. 1997. Cis-acting signals involved in termination of vesicular stomatitis virusmRNAsynthesis include the conserved AUAC and the U7 signal for polyadenylation. J Virol 71:8718-8725.
23. Cowton VM, McGivern DR, Fearns R. 2006. Unravelling the complexities of respiratory syncytial virus RNA synthesis. J Gen Virol 87:1805-1821. http://dx.doi.org/10.1099/vir.0.81786-0.
24. Noton SL, Fearns R. 2015. Initiation and regulation of paramyxovirus transcription and replication. Virology 479-480C:545-554. http://dx.doi.org/10.1016/j.virol.2015.01.014.
25. Dickens LE, Collins PL, Wertz GW. 1984. Transcriptional mapping of human respiratory syncytial virus. J Virol 52:364-369.
26. Fearns R, Peeples ME, Collins PL. 2002. Mapping the transcription and replication promoters of respiratory syncytial virus. J Virol 76:1663-1672. http://dx.doi.org/10.1128/JVI.76.4.1663-1672.2002.
27. Collins PL, Dickens LE, Buckler-White A, Olmsted RA, Spriggs MK, Camargo E, Coelingh KV. 1986. Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc Natl Acad Sci USA 83:4594-4598. http://dx.doi.org/10.1073/pnas.83.13.4594.
28. Kuo L, Grosfeld H, Cristina J, Hill MG, Collins PL. 1996. Effects of mutations in the gene-start and gene-end sequence motifs on transcription of monocistronic and dicistronic minigenomes of respiratory syncytial virus. J Virol 70:6892-6901.
29. Tremaglio CZ, Noton SL, Deflube LR, Fearns R. 2013. Respiratory syncytial virus polymerase can initiate transcription from position 3 of the leader promoter. J Virol 87:3196-3207. http://dx.doi.org/10.1128/JVI.02862-12.
30. Noton SL, Fearns R. 2011. The first two nucleotides of the respiratory syncytial virus antigenome RNA replication product can be selected independently of the promoter terminus. RNA 17:1895-1906. http://dx.doi.org/10.1261/rna.2813411.
31. Gubbay O, Curran J, Kolakofsky D. 2001. Sendai virus genome synthesis and assembly are coupled: a possible mechanism to promote viral RNA polymerase processivity. J Gen Virol 82:2895-2903.
32. McGivern DR, Collins PL, Fearns R. 2005. Identification of internal sequences in the 3' leader region of human respiratory syncytial virus that enhance transcription and confer replication processivity. J Virol 79: 2449-2460. http://dx.doi.org/10.1128/JVI.79.4.2449-2460.2005.
33. Noton SL, Cowton VM, Zack CR, McGivern DR, Fearns R. 2010. Evidence that the polymerase of respiratory syncytial virus initiates RNA replication in a nontemplated fashion. Proc Natl Acad Sci USA 107: 10226-10231. http://dx.doi.org/10.1073/pnas.0913065107.
34. Peeples ME, Collins PL. 2000. Mutations in the 5' trailer region of a respiratory syncytial virus minigenome which limit RNA replication to one step. J Virol 74:146-155. http://dx.doi.org/10.1128/JVI.74.1.146-155.2000.
35. Hanley LL, McGivern DR, Teng MN, Djang R, Collins PL, Fearns R. 2010. Roles of the respiratory syncytial virus trailer region: effects of mutations on genome production and stress granule formation. Virology 406:241-252. http://dx.doi.org/10.1016/j.virol.2010.07.006.
36. Noton SL, Aljabr W, Hiscox JA, Matthews DA, Fearns R. 2014. Factors affecting de novo RNA synthesis and back-priming by the respiratory syncytial virus polymerase. Virology 462-463:318-327. http://dx.doi.org/10.1016/j.virol.2014.05.032.
37. Laganas VA, Dunn EF, McLaughlin RE, Tiong-Yip CL, Yuzhakov O, Isabella VM, Hill P, Yu Q. 2015. Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen. Antiviral Res 115:71-74. http://dx.doi.org/10.1016/j.antiviral.2014.12.012.
38. Mason SW, Lawetz C, Gaudette Y, Do F, Scouten E, Lagace L, Simoneau B, Liuzzi M. 2004. Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. Nucleic Acids Res 32:4758-4767. http://dx.doi.org/10.1093/nar/gkh809.
39. Matharu DS, Flaherty DP, Simpson DS, Schroeder CE, Chung D, Yan D, Noah JW, Jonsson CB, White EL, Aube J, Plemper RK, Severson WE, Golden JE. 2014. Optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block RNAdependent RNA-polymerase complex activity. J Med Chem 57:10314-10328. http://dx.doi.org/10.1021/jm500902x.
40. Sudo K, Miyazaki Y, Kojima N, Kobayashi M, Suzuki H, Shintani M, Shimizu Y. 2005. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res 65:125-131. http://dx.doi.org/10.1016/j.antiviral.2004.12.002.
41. Xiong H, Foulk M, Aschenbrenner L, Fan J, Tiong-Yip CL, Johnson KD, Moustakas D, Fleming PR, Brown DG, Zhang M, Ferguson D, Wu D, Yu Q. 2013. Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor. Bioorg Med Chem Lett 23:6789-6793. http://dx.doi.org/10.1016/j.bmcl.2013.10.018.
42. Tiong-Yip CL, Aschenbrenner L, Johnson KD, McLaughlin RE, Fan J, Challa S, Xiong H, Yu Q. 2014. Characterization of a respiratory syncytial virus L protein inhibitor. Antimicrob Agents Chemother 58:3867-3873. http://dx.doi.org/10.1128/AAC.02540-14.
43. Jin H, Clarke D, Zhou HZ, Cheng X, Coelingh K, Bryant M, Li S. 1998. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology 251:206-214. http://dx.doi.org/10.1006/viro.1998.9414.
44. Grosfeld H, Hill MG, Collins PL. 1995. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA. J Virol 69:5677-5686.
45. Wyatt LS, Moss B, Rozenblatt S. 1995. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 210:202-205. http://dx.doi.org/10.1006/viro.1995.1332.
46. Carlos TS, Fearns R, Randall RE. 2005. Interferon-induced alterations in the pattern of parainfluenza virus 5 transcription and protein synthesis and the induction of virus inclusion bodies. J Virol 79:14112-14121. http://dx.doi.org/10.1128/JVI.79.22.14112-14121.2005.
47. Munday DC, Wu W, Smith N, Fix J, Noton SL, Galloux M, Touzelet O, Armstrong SD, Dawson JM, Aljabr W, Easton AJ, Rameix-Welti MA, de Oliveira AP, Simabuco FM, Ventura AM, Hughes DJ, Barr JN, Fearns R, Digard P, Eleouet JF, Hiscox JA. 2015. Interactome analysis of the human respiratory syncytial virus RNA polymerase complex identifies protein chaperones as important cofactors that promote L-protein stability and RNA synthesis. J Virol 89:917-930. http://dx.doi.org/10.1128/JVI.01783-14.
48. Fearns R, Peeples ME, Collins PL. 1997. Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome. Virology 236:188-201. http://dx.doi.org/10.1006/viro.1997.8734.
49. Yin YW, Steitz TA. 2002. Structural basis for the transition from initiation to elongation transcription in T7 RNA polymerase. Science 298: 1387-1395. http://dx.doi.org/10.1126/science.1077464.
50. van Dijk AA, Makeyev EV, Bamford DH. 2004. Initiation of viral RNAdependent RNA polymerization. J Gen Virol 85:1077-1093. http://dx.doi.org/10.1099/vir.0.19731-0.
51. Cortese CK, Feller JA, Moyer SA. 2000. Mutations in domain V of the Sendai virus L polymerase protein uncouple transcription and replication and differentially affect replication in vitro and in vivo. Virology 277:387-396. http://dx.doi.org/10.1006/viro.2000.0615.
52. Feller JA, Smallwood S, Horikami SM, Moyer SA. 2000. Mutations in conserved domains IV and VI of the large (L) subunit of the Sendai virus RNA polymerase give a spectrum of defective RNA synthesis phenotypes. Virology 269:426-439. http://dx.doi.org/10.1006/viro.2000.0234.
53. Dochow M, Krumm SA, Crowe JE, Jr, Moore ML, Plemper RK. 2012. Independent structural domains in paramyxovirus polymerase protein. J Biol Chem 287:6878-6891. http://dx.doi.org/10.1074/jbc.M111.325258.
54. Wang G, Deval J, Hong J, Dyatkina N, Prhavc M, Taylor J, Fung A, Jin Z, Stevens SK, Serebryany V, Liu J, Zhang Q, Tam Y, Chanda SM, Smith DB, Symons JA, Blatt LM, Beigelman L. 2015. Discovery of 4=-chloromethyl-2'-deoxy-3', 5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem 58:1862-1878. http://dx.doi.org/10.1021/jm5017279.